麗珠集團(000513.SZ):注射用JP-1366獲得藥物臨牀試驗批准通知書
格隆匯2月12日丨麗珠集團(000513.SZ)公佈,收到國家藥品監督管理局核准簽發的《藥物臨牀試驗批准通知書》,批准注射用JP-1366開展臨牀試驗。JP-1366是一款新型鉀離子競爭性酸阻滯劑(P-CAB),其作用機制為競爭性結合胃壁細胞內H+/K+-ATP酶的鉀離子結合部位,抑制胃酸的分泌。P-CAB具有起效快、抑酸效果佳且作用持久、個體差異小、藥物相互作用少等特點。本次注射用JP-1366申請開展臨牀試驗的適應症為消化性潰瘍出血。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.